Welcome to the European Association for Cancer Research
Europe’s membership association for cancer researchers

ESMO Symposium on Signalling Pathways in Cancer 2018

EACR Meeting Bursaries for the ESMO Symposium on Signalling Pathways in Cancer 2018: Cyclin-dependent kinases (CDKs)

Organised by ESMO in partnership with the EACR

23 - 24 March 2018 || Vall d’Hebron Institute of Oncology, Barcelona, Spain

The 6th edition of the ESMO Symposium on Signalling Pathways in Cancer, in partnership with the European Association for Cancer Research (EACR), will focus on Cyclin-dependent kinases (CDKs).

It is the next important step in a strategic collaboration between basic scientists and translational and clinical researchers. The aim is to foster close cooperation among academics, clinical and industry researchers in a highly interactive hands-on professional environment.

Up to 10 EACR bursaries available

Up to 10 bursaries will be awarded to assist members of the European Association for Cancer Research to attend the symposium. The bursaries provide a registration and funds to support travel and accommodation.


  • Members who are PhD students or who completed their PhD (or equivalent degree) less than ten years ago are eligible to apply. Exceptions may be made in the case of researchers who have had a professional break, such as illness or parental leave.
  • Applicants must have held a valid membership of the EACR for at least three months prior to the application deadline.


Apply now

Application deadline: Thursday 18 January 2018

Click here to download the application form

Any questions?

Application contact: Kathryn Wass:




Sorry. You need to upgrade your browser

You are using Internet Explorer 8

This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.

Thank you.